AstraZeneca PLC ADR Rises Wednesday, Outperforms Market

Dow Jones11-14

DJ AstraZeneca PLC ADR Rises Wednesday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights.

The AstraZeneca PLC ADR $(AZN)$ inched 0.15% higher to $65.29 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.11% to 43,958.19 and the NASDAQ Composite Index falling 0.26% to 19,230.73.

This was the ADR's third consecutive day of gains.

AstraZeneca PLC ADR closed $22.39 short of its 52-week high ($87.68), which the company achieved on August 30th.

The ADR demonstrated a mixed performance when compared to some of its competitors Wednesday, as Eli Lilly & Co. $(LLY)$ fell 0.86% to $811.81, Biogen Inc. $(BIIB)$ fell 1.48% to $165.79, and Johnson & Johnson $(JNJ)$ rose 0.39% to $153.24.

Trading volume (6.6 M) eclipsed its 50-day average volume of 5.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled November 13, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

November 13, 2024 17:22 ET (22:22 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment